family with sequence similarity 209 member BGenealiases: C20orf107 · dJ1153D9.4
Q-omics provides the consensus-scored FAM209B profile across patient tissues and cancer cell-line models. FAM209B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, FAM209B is differentially expressed in 6, with the highest sampling consensus in BLCA. Additionally, FAM209B RNA expression shows 13,612 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, and THYM as cancer lineages where FAM209B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM209B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM209B survival associations across molecular data types. FAM209B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM209B RNA expression–survival associations across cancer types. High FAM209B expression shows unfavorable associations in KICH, UVM and LUSC, but favorable associations in BLCA, CESC and PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for FAM209B RNA expression.
This table summarizes FAM209B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM209B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM209B shows lower tumor expression in KIRP and LUSC and higher tumor expression in BLCA, LIHC, STAD and CHOL. The BLCA box plot shows higher FAM209B RNA expression in tumor versus normal tissue (log2 FC = +0.433, t-test p = .012).
This table shows molecular features associated with FAM209B in patient tissues and cancer cell lines. In patient samples, FAM209B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM209B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
